A James M Daveson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5287676/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 244-252.	3.7	27
2	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Medicine, 2020, 18, 362.	5.5	22
3	Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on glutenâ€free diet. GastroHep, 2020, 2, 22-30.	0.6	43
4	Editorial: inaccuracies in attribution of symptoms due to gluten—not just in those with selfâ€reported noncoeliac gluten sensitivity. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 403-404.	3.7	1
5	Randomised clinical trial: a placeboâ€controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 547-555.	3.7	35
6	Elevated serum interleukinâ $\in 2$ after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 901-910.	3.7	51
7	Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clinical and Experimental Immunology, 2019, 199, 68-78.	2.6	36
8	Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. The Lancet Gastroenterology and Hepatology, 2017, 2, 479-493.	8.1	113
9	Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. EBioMedicine, 2017. 26. 78-90.	6.1	51
10	Discrepancies in genetic testing results for coeliac disease: call for standardised testing and reporting. Medical Journal of Australia, 2017, 207, 179-180.	1.7	1
11	846 Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2®, a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD). Gastroenterology, 2016, 150, S180.	1.3	2
12	Inflammatory Bowel Disease Clinical. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 127-155.	2.8	4
13	Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an <scp>A</scp> ustralasian perspective. Internal Medicine Journal, 2015, 45, 441-450.	0.8	40
14	Characterising the Mucosal and Systemic Immune Responses to Experimental Human Hookworm Infection. PLoS Pathogens, 2012, 8, e1002520.	4.7	110
15	Small bowel endoscopy and coeliac disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 315-323.	2.4	8
16	Suppression of Inflammatory Immune Responses in Celiac Disease by Experimental Hookworm Infection. PLoS ONE, 2011, 6, e24092.	2.5	105
17	Effect of Hookworm Infection on Wheat Challenge in Celiac Disease – A Randomised Double-Blinded Placebo Controlled Trial. PLoS ONE, 2011, 6, e17366.	2.5	188
18	A case of periportal fibrosis in a Sudanese refugee. Medical Journal of Australia, 2008, 188, 677-678.	1.7	0

#	Article	IF	CITATIONS
19	Future Perspectives of Small Bowel Capsule Endoscopy. , 2008, , 262-270.		3
20	A case of an isolated gastric variceal bleed secondary to a pancreatic neuroendocrine tumour. European Journal of Gastroenterology and Hepatology, 2007, 19, 1144-1148.	1.6	10